参 考 文 献
[1]
Vera-LlonchM, OsterG, HagiwaraM，et al.
Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma[J].
Cancer，
2006，
106(
2)：
329-
336.
.
[2]
陈谦明.
口腔黏膜病学[M].
3版.
北京：
人民卫生出版社，
2008：
77-
78.
ChenQM. Oral mucosology[M].3ed. Beijing：People′s health publishing house，2008：77-78.
[3]
PopovtzerA, EisbruchA.
Advances in radiation therapy of head and neck cancer[J].
Exp Rev Anticancer Ther，
2008，
8(
4)：
633-
644.
.
[4]
EltingLS, CooksleyCD, ChambersMS，et al.
Risk，outcomes，and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies[J].
Int J Radiat Oncol Biol Phys，
2007，
68(
4)：
1110-
1120.
.
[5]
EtizD, OrhanB, DemirustuC，et al.
Comparison of radiation-induced oral mucositis scoring systems[J].
Tumori，
2002，
88(
5)：
379-
384.
[6]
RiesenbeckD, DorrW
Documentation of radiation-induced oral mucositis. Scoring systems[J].
Strahlenther Onkol，
1998，
174(
Suppl 3)：
44-
46.
[7]
SonisST, EilersJP, EpsteinJB，et al.
Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy[J].
Cancer，
1999，
85(
10)：
2103-
2113.
[9]
RubensteinEB, PetersonDE, SchubertM，et al.
Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis[J].
Cancer，
2004，
100(
9
Suppl)：
2026-
2046.
.
[10]
LallaRV, BowenJ, BaraschA，et al.
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy[J].
Cancer，
2014，
120(
10)：
1453-
1461.
.
[11]
PetersonDE, Boers-DoetsCB, BensadounRJ，et al.
Management of oral and gastrointestinal mucosal injury：ESMO Clinical Practice Guidelines for diagnosis，treatment，and follow-up[J].
Ann Oncol，
2015，
26(
Suppl 5)：
v139-
51.
.
[12]
ShankarA, RoyS, BhandariM，et al.
Current trends in management of oral mucositis in cancer treatment[J].
As Pac J Cancer Prev，
2017，
18(
8)：
2019-
2026.
.
[13]
EilersJ, MillionR.
Prevention and management of oral mucositis in patients with cancer[J].
Semin Oncol Nurs，
2007，
23(
3)：
201-
212.
.
[14]
SonisST
Mucositis：the impact，biology and therapeutic opportunities of oral mucositis[J].
Oral Oncol，
2009，
45(
12)：
1015-
1020.
.
[15]
KhawA, LoganR, KeefeD，et al.
Radiation-induced oral mucositis and periodontitis—proposal for an inter-relationship[J].
Oral Dis.
2014
；
20(
3)：
e7-
18.
.
[16]
HsiungCY, TingHM, HuangHY，et al.
Parotid-sparing intensity-modulated radiotherapy (IMRT) for nasopharyngeal carcinoma：preserved parotid function after IMRT on quantitative salivary scintigraphy，and comparison with historical data after conventional radiotherapy[J].
Int J Radiat Oncol Biol Phys，
2006，
66(
2)：
454-
461.
.
[17]
RomesserPB, CahlonO, ScherED，et al.
Proton beam reirradiation for recurrent head and neck cancer：multi-institutional report on feasibility and early outcomes[J].
Int J Radiat Oncol Biol Phys，
2016，
95(
2)：
386-
395.
.
[18]
VogelJ, BothS, KirkM，et al.
Proton therapy for pediatric head and neck malignancies[J].
Pediatr Blood Cancer.
2018
；
65(
2).
.
[19]
RomesserPB, CahlonO, ScherE，et al.
Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation[J].
Radiother Oncol，
2016，
118(
2)：
286-
292.
.
[20]
BourhisJ, LapeyreM, TortochauxJ，et al.
Phase Ⅲ randomized trial of very accelerated radiation therapy compared with conventional radiation therapy in squamous cell head and neck cancer：a GORTEC trial[J].
J Clin Oncol，
2006，
24(
18)：
2873-
2878.
.
[21]
FuKK, PajakTF, TrottiA，et al.
A radiation therapy oncology group (RTOG) phase Ⅲ randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas：first report of RTOG 9003[J].
Int J Radiat Oncol Biol Phys，
2000，
48(
1)：
7-
16.
[22]
XuT, LiuY, DouS，et al.
Weekly cetuximab concurrent with IMRT aggravated radiation-induced oral mucositis in locally advanced nasopharyngeal carcinoma：Results of a randomized phase Ⅱ study[J].
Oral Oncol，
2015，
51(
9)：
875-
879.
.
[23]
TrottiA, BellmLA, EpsteinJB，et al.
Mucositis incidence，severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy：a systematic literature review[J].
Radiother Oncol，
2003，
66(
3)：
253-
262.
[24]
MallickS, BensonR, RathGK.
Radiation induced oral mucositis：a review of current literature on prevention and management[J].
Eur Arch Otorhinolaryngol，
2016，
273(
9)：
2285-
2293.
.
[25]
GuptaT, KannanS, Ghosh-LaskarS，et al.
Systematic review and Meta-analysis of conventionally fractionated concurrent chemoradiotherapy versus altered fractionation Radiotherapy Alone in the Definitive Management of locoregionally advanced head and neck squamous cell carcinoma[J].
Clin Oncol (R Coll Radiol)，
2016，
28(
1)：
50-
61.
.
[26]
NarayanS, LehmannJ, ColemanMA，et al.
Prospective evaluation to establish a dose response for clinical oral mucositis in patients undergoing head-and-neck conformal radiotherapy[J].
Int J Radiat Oncol Biol Phys，
2008，
72(
3)：
756-
762.
.
[27]
WangZH, ZhangSZ, ZhangZY，et al.
Protecting the oral mucosa in patients with oral tongue squamous cell carcinoma treated postoperatively with intensity-modulated radiotherapy：a randomized study[J].
Laryngoscope，
2012，
122(
2)：
291-
298.
.
[28]
KhuntiaD, HarrisJ, BentzenS，et al.
Increased oral mucositis after IMRT versus non-IMRT when combined with cetuximab and cisplatin or docetaxel for head and neck cancer：preliminary results of RTOG 0234[J].
Int J Radiat Oncol Biol Phys，
2008，
72(
1)：
S33.
.
[29]
殷蔚伯，申文江，王绿化.
放射治疗损伤[M].
北京：
中国医药科技出版社，
2001：
79-
81.
YinWB, ShenWJ, WangLH. Radiotherapy Injury[M]. Beijing：China medical science and technology press，2001：79-81.
[30]
CalaisG, AlfonsiM, BardetE，et al.
Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma[J].
J Natl Cancer Inst，
1999，
91(
24)：
2081-
2086.
[31]
OlmiP, CrispinoS, FallaiC，et al.
Locoregionally advanced carcinoma of the oropharynx：conventional radiotherapy vs.accelerated hyperfractionated radiotherapy vs.concomitant radiotherapy and chemotherapy—a multicenter randomized trial[J].
Int J Radiat Oncol Biol Phys，
2003，
55(
1)：
78-
92.
[32]
ForastiereAA, GoepfertH, MaorM，et al.
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer[J].
N Engl J Med，
2003，
349(
22)：
2091-
2098.
.
[33]
CooperJS, PajakTF, ForastiereAA，et al.
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck[J].
N Engl J Med，
2004，
350(
19)：
1937-
44.
.
[34]
BernierJ, DomengeC, OzsahinM，et al.
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer[J].
N Engl J Med，
2004，
350(
19)：
1945-
52.
.
[35]
XuC, ZhangLH, ChenYP，et al.
Chemoradiotherapy versus radiotherapy alone in stage Ⅱ nasopharyngeal carcinoma：a systemic review and Meta-analysis of 2138 patients[J].
J Cancer，
2017，
8(
2)：
287-
297.
.
[36]
BlanchardP, LeeA, MarguetS，et al.
Chemotherapy and radiotherapy in nasopharyngeal carcinoma：an update of the MAC-NPC meta-analysis[J].
Lancet Oncol，
2015，
16(
6)：
645-
655.
.
[37]
ChenL, HuCS, ChenXZ，et al.
Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma：a phase 3 multicentre randomised controlled trial[J].
Lancet Oncol，
2012，
13(
2)：
163-
171.
.
[38]
LiY, ChenQY, TangLQ，et al.
Concurrent chemoradiotherapy with or without cetuximab for stage Ⅱ to Ⅳb nasopharyngeal carcinoma：a case-control study[J].
BMC Cancer，
2017，
17(
1)：
567.
.
[39]
BjarnasonGA, MackenzieRG, NabidA，et al.
Comparison of toxicity associated with early morning versus late afternoon radiotherapy in patients with head-and-neck cancer：a prospective randomized trial of the National Cancer Institute of Canada Clinical Trials Group (HN3)[J].
Int J Radiat Oncol Biol Phys，
2009，
73(
1)：
166-
172.
.
[40]
BensingerW, SchubertM, AngKK，et al.
NCCN task force report.prevention and management of mucositis in cancer care[J].
J Natl Compr Canc Netw，
2008，
6(
Suppl 1)：
S1-21, S22-24.
[41]
PetersonDE, BensadounRJ, RoilaF，et al.
Management of oral and gastrointestinal mucositis：ESMO Clinical Practice Guidelines[J].
Ann Oncol，
2011，
22(
Suppl 6)：
vi78-
84.
.
[42]
McGuireDB, FultonJS, ParkJ，et al.
Systematic review of basic oral care for the management of oral mucositis in cancer patients[J].
Support Care Cancer，
2013，
21(
11)：
3165-
3177.
.
[43]
PsSK, BalanA, SankarA，et al.
Radiation induced oral mucositis[J].
Indian J Palliat Care，
2009，
15(
2)：
95-
102.
.
[44]
SaarilahtiK, KajantiM, JoensuuT，
Comparison of granulocyte-macrophage colony-stimulating factorand sucralfate mouthwashes in the prevention of radiation-induced mucositis：a double-blind prospective randomized phase Ⅲ study[J].
Int J Radiat Oncol Biol Phys.
2002
；
54(
2)：
479-
85.
[45]
WagnerW, AlfrinkM, HausU, MattJ.
Treatment of irradiation-induced mucositis with growth factors (rhGM-CSF) in patients with head and neck cancer[J].
Anticancer Res，
1999，
19(
1B)：
799-
803.
[46]
MantovaniG, MassaE, AstaraG，et al.
Phase Ⅱ clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy-and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients：an evaluation of effectiveness，safety and costs[J].
Oncol Rep，
2003，
10(
1)：
197-
206.
.
[47]
RyuJK, SwannS, LeVequeF，et al.
The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients：a double-blind placebo-controlled prospective phase Ⅲ study by Radiation Therapy Oncology Group 9901[J].
Int J Radiat Oncol Biol Phys，
2007，
67(
3)：
643-
650.
.
[48]
HoffmanKE, PughSL, JamesJL，et al.
The impact of concurrent granulocyte-macrophage colony-stimulating factor on quality of life in head and neck cancer patients：results of the randomized，placebo-controlled Radiation Therapy Oncology Group 9901 trial[J].
Qual Life Res，
2014，
23(
6)：
1841-
1858.
.
[49]
JudithE, Raber-DurlacherI, von BültzingslöwenS.
Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients[J].
Support Care Cancer，
2013，
21(
2)：
343-
355.
.
[50]
李素艳，高黎，殷蔚伯，等.
金因肽对急性放射性黏膜炎及皮炎的作用[J].
中华放射肿瘤学杂志，
2002，
11(
1)：
30-
32.
LiSY, GaoL, YinWB，et al. Effects of ginin on acute radiation mucositis and dermatitis[J]. Chin J Radiat Oncol，2002，11(1)：30-32.
[51]
WuHG, SongSY, KimYS，et al.
Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy，with or without chemotherapy，for head and neck cancer：a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial[J].
Cancer，
2009，
115(
16)：
3699-
3708.
.
[52]
Nicolatou-GalitisO, SarriT, BowenJ，et al.
Systematic review of amifostine for the management of oral mucositis in cancer patients[J].
Support Care Cancer，
2013，
21(
1)：
357-
364.
.
[53]
TsujimotoT, YamamotoY, WasaM，et al.
L-glutamine decreases the severity of mucositis induced by chemoradiotherapy in patients with locally advanced head and neck cancer：a double-blind，randomized，placebo-controlled trial[J].
Oncol Rep，
2015，
33(
1)：
33-
39.
.
[54]
QuinnB.
Efficacy of a supersaturated calcium phosphate oral rinse for the prevention and treatment of oral mucositis in patients receiving high-dose cancer therapy：a review of current data[J].
Eur J Cancer Care (Engl)，
2013，
22(
5)：
564-
579.
.
[55]
LambrechtM, MercierC, GeussensY，et al.
The effect of a supersaturated calcium phosphate mouth rinse on the development of oral mucositis in head and neck cancer patients treated with (chemo) radiation：a single-center，randomized，prospective study of a calcium phosphate mouth rinse＋ standard of care versus standard of care[J].
Support Care Cancer，
2013，
21(
10)：
2663-
2670.
.
[56]
SironiM, MilaneseC, VecchiA，et al.
Benzydamine inhibits the release of tumor necrosis factor-alpha and monocyte chemotactic protein-1 by Candida albicans-stimulated human peripheral blood cells[J].
Int J Clin Lab Res，
1997，
27(
2)：
118-
122.
[58]
SironiM, PozziP, PolentaruttiN，et al.
Inhibition of inflammatory cytokine production and protection against endotoxin toxicity by benzydamine[J].
Cytokine，
1996，
8(
9)：
710-
716.
[58]
EpsteinJB, SilvermanS, PaggiarinoDA，et al.
Benzydamine HCl for prophylaxis of radiation-induced oral mucositis：results from a multicenter，randomized，double-blind，placebo-controlled clinical trial[J].
Cancer，
2001，
92(
4)：
875-
885.
[59]
KazemianA, KamianS, AghiliM，et al.
Benzydamine for prophylaxis of radiation-induced oral mucositis in head and neck cancers：a double-blind placebo-controlled randomized clinical trial[J].
Eur J Cancer Care (Engl)，
2009，
18(
2)：
174-
178.
.
[60]
Nicolatou-GalitisO, SarriT, BowenJ，et al.
Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients[J].
Support Care Cancer，
2013，
21(
11)：
3179-
3189.
.
[61]
SaundersDP, EpsteinJB, EladS，et al.
Systematic review of antimicrobials，mucosal coating agents，anesthetics，and analgesics for the management of oral mucositis in cancer patients[J].
Support Care Cancer，
2013，
21(
11)：
3191-
3207.
.
[62]
林冰，郎锦义，张鹏.
放化疗全程配合不同中药组方治疗鼻咽癌的临床观察[J].
四川中医，
2014，
32(
9)：
71-
73.
LinB, LangJY, ZhangP. Clinical observation on the treatment of nasopharyngeal carcinoma by radiotherapy and chemotherapy combined with different traditional chinese medicine formulas[J]. Sichuan Tradit Chin Med，2014，32(9)：71-73.
[63]
ZhengB, ZhuX, LiuM，et al.
Randomized，double-blind，placebo-controlled trial of Shuanghua Baihe tablets to prevent oral mucositis in patients with nasopharyngeal cancer undergoing chemoradiation therapy[J].
Int J Radiat Oncol Biol Phys，
2018，
100(
2)：
418-
426.
.
[64]
KongM, HwangDS, YoonSW，et al.
The effect of clove-based herbal mouthwash on radiation-induced oral mucositis in patients with head and neck cancer：a single-blind randomized preliminary study[J].
Onco Targets Ther，
2016，
9：
4533-
4538.
.
[65]
LuoY, FengM, FanZ，et al.
Effect of Kangfuxin solution on chemo/radiotherapy-induced mucositis in nasopharyngeal carcinoma patients：a multicenter，prospective randomized phase Ⅲ clinical study[J].
Evid Based Complement Alternat Med，
2016，
2016：
8692343.
.
[66]
MoseS, AdamietzIA, SaranF，et al.
Can prophylactic application of immunoglobulin decrease radiotherapy-induced oral mucositis？[J].
Am J Clin Oncol，
1997，
20(
4)：
407-
411.
[67]
AhmadiA.
Potential prevention：Aloe vera mouthwash may reduce radiation-induced oral mucositis in head and neck cancer patients[J].
Chin J Integr Med，
2012，
18(
8)：
635-
640.
.
[68]
Santos-SilvaAR, RosaGB, EduardoCP，et al.
Increased risk for radiation-related caries in cancer patients using topical honey for the prevention of oral mucositis[J].
Int J Oral Maxillofac Surg，
2011，
40(
11)：
1335-
1336.
.
[69]
LinBM, StarmerHM, GourinCG.
The relationship between depressive symptoms，quality of life，and swallowing function in head and neck cancer patients 1 year after definitive therapy[J].
Laryngoscope，
2012，
122(
7)：
1518-
1525.
.
[70]
BassoFG, PansaniTN, SoaresDG，et al.
Biomodulation of inflammatory cytokines related to oral mucositis by low-level laser therapy[J].
Photochem Photobiol，
2015，
91(
4)：
952-
956.
.
[71]
KannanV, BapsyPP, AnanthaN，et al.
Efficacy and safety of granulocyte macrophage-colony stimulating factor (GM-CSF) on the frequency and severity of radiation mucositis in patients with head and neck carcinoma[J].
Int J Radiat Oncol Biol Phys，
1997，
37(
5)：
1005-
1010.
[72]
McAleeseJJ, BishopKM, A′HernR，et al.
Randomized phase Ⅱ study of GM-CSF to reduce mucositis caused by accelerated radiotherapy of laryngeal cancer[J].
Br J Radiol，
2006，
79(
943)：
608-
613.
.
[73]
SprinzlGM, GalvanO, de VriesA，et al.
Local application of granulocytemacrophage colony stimulating factor (GM-CSF) for the treatment of oral mucositis[J].
Eur J Cancer，
2001，
37(
16)：
2003-
2009.
.
[74]
Nishii1M, SoutomeS, KawakitaA.
Factors associated with severe oral mucositis and candidiasis in patients undergoing radiotherapy for oral and oropharyngeal carcinomas：a retrospective multicenter study of 326 patients[J].
Support Care Cancer.
2019
.
.
[75]
PillsburyHC Ⅲ, WebsterWP, RosenmanJ.
Prostaglandin inhibitorand radiotherapy in advanced head and neck cancers[J].
Arch Otolaryngol Head Neck Surg，
1986，
112(
5)：
552-
553.
.
 - 中华放射肿瘤学杂志_files/weixin.gif)
 - 中华放射肿瘤学杂志_files/sinaminiblog.gif)
 - 中华放射肿瘤学杂志_files/youdaonote.gif)
 - 中华放射肿瘤学杂志_files/twitter.gif)
 - 中华放射肿瘤学杂志_files/facebook.gif)
 - 中华放射肿瘤学杂志_files/gplus.gif)
 - 中华放射肿瘤学杂志_files/evernote.gif)
 - 中华放射肿瘤学杂志_files/reddit.gif)
 - 中华放射肿瘤学杂志_files/diigo.gif)
 - 中华放射肿瘤学杂志_files/linkedin.gif)
 - 中华放射肿瘤学杂志_files/instapaper.gif)
 - 中华放射肿瘤学杂志_files/itieba.gif)
 - 中华放射肿瘤学杂志_files/friendfeed.gif)
 - 中华放射肿瘤学杂志_files/douban.gif)
 - 中华放射肿瘤学杂志_files/clipboard.gif)
 - 中华放射肿瘤学杂志_files/favorite.gif)
 - 中华放射肿瘤学杂志_files/gmail.gif)
 - 中华放射肿瘤学杂志_files/poco.gif)
 - 中华放射肿瘤学杂志_files/readitlater.gif)